BioMarin Pharmaceutical(BMRN) - 2025 Q1 - Earnings Call Presentation

Financial Performance - Total revenues for Q1 2025 reached $745 million, a 15% year-over-year increase[13] - VOXZOGO revenues experienced substantial growth, increasing by 40% year-over-year to $214 million[14] - Enzyme Therapies revenues grew by 8% year-over-year, driven by PALYNZIQ's 22% growth[14, 17] - Non-GAAP Diluted EPS increased by 59% year-over-year, reaching $1.13[14] - GAAP Diluted Earnings per Share (EPS) showed significant improvement, increasing by 107% to $0.95[14] - Non-GAAP Operating Margin percentage was 35.7%, an increase of 11.9 percentage points year-over-year[14] Guidance and Pipeline - Full-year 2025 guidance reaffirmed for Total Revenues ($3.1 billion to $3.2 billion), Non-GAAP Operating Margin (32% to 33%), and Non-GAAP Diluted EPS ($4.20 to $4.40)[20] - Initial data for BMN 351 for DMD is expected in the second half of 2025[17] - Pivotal study with VOXZOGO in hypochondroplasia fully enrolled in April 2025, with potential launch in 2027[17] - Positive pivotal topline results for PALYNZIQ in adolescents ages 12-17 shared in April, supporting planned submissions to regulatory authorities in the U.S and EU in 2H'25[17]